{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:42:38Z","timestamp":1771483358684,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed Incorporated","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03553-9","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:14:59Z","timestamp":1740150899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Insights from the European Nontuberculous mycobacterial pulmonary disease PAtient Disease Experience (ENPADE) survey\u2013 exploring disease burden and impact"],"prefix":"10.1186","volume":"25","author":[{"given":"Michal","family":"Shteinberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Obradovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roald","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hoenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger J.","family":"Legtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas L. G.","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Lorent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"6","key":"3553_CR1","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s12325-023-02519-9","volume":"40","author":"C Hoenig","year":"2023","unstructured":"Hoenig C, Van Der Laan R, Reimann A, Hoffmann M, Tyler S, Wiesmann C, et al. Eliciting patient insights on the Burden of Nontuberculous Mycobacterial Lung Disease (NTM-LD) and Healthcare gaps in Germany through qualitative semi-structured interviews. Adv Ther. 2023;40(6):2915\u201326.","journal-title":"Adv Ther"},{"issue":"4","key":"3553_CR2","doi-asserted-by":"publisher","first-page":"1602109","DOI":"10.1183\/13993003.02109-2016","volume":"49","author":"R Diel","year":"2017","unstructured":"Diel R, Jacob J, Lampenius N, Loebinger M, Nienhaus A, Rabe KF, et al. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. 2017;49(4):1602109.","journal-title":"Eur Respir J"},{"key":"3553_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/1471-2458-10-612","volume":"10","author":"JE Moore","year":"2010","unstructured":"Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995\u20132006. BMC Public Health. 2010;10:612.","journal-title":"BMC Public Health"},{"key":"3553_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","volume":"11","author":"CN Ratnatunga","year":"2020","unstructured":"Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of Non-tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303.","journal-title":"Front Immunol"},{"key":"3553_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12879-016-1521-3","volume":"16","author":"NM Shah","year":"2016","unstructured":"Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007\u20132012. BMC Infect Dis. 2016;16:195.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"3553_CR6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.chest.2023.06.014","volume":"164","author":"MR Loebinger","year":"2023","unstructured":"Loebinger MR, Quint JK, Laan R, van der, Obradovic M, Chawla R, Kishore A, et al. Risk factors for Nontuberculous Mycobacterial Pulmonary Disease: a systematic literature review and Meta-analysis. Chest. 2023;164(5):1115\u201324.","journal-title":"Chest"},{"issue":"6","key":"3553_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5588\/ijtld.17.0433","volume":"22","author":"T Asakura","year":"2018","unstructured":"Asakura T, Ishii M, Ishii K, Suzuki S, Namkoong H, Okamori S, et al. Health-related QOL of elderly patients with pulmonary M. avium complex disease in a university hospital. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2018;22(6):695\u2013703.","journal-title":"Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis"},{"issue":"11","key":"3553_CR8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1080\/17476348.2021.1987891","volume":"15","author":"J Van Ingen","year":"2021","unstructured":"Van Ingen J, Obradovic M, Hassan M, Lesher B, Hart E, Chatterjee A, et al. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. 2021;15(11):1387\u2013401.","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"3553_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: an Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020;71(4):e1\u201336.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3553_CR10","doi-asserted-by":"publisher","first-page":"00807","DOI":"10.1183\/23120541.00807-2020","volume":"7","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Boyd J, Aliberti S, Polverino E, Harris B, Berg T, et al. What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. ERJ Open Res. 2021;7(1):00807\u20132020.","journal-title":"ERJ Open Res"},{"key":"3553_CR11","unstructured":"Research C, for DE. and. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients [Internet]. FDA; 2022 [cited 2024 May 6]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients"},{"issue":"2","key":"3553_CR12","doi-asserted-by":"publisher","first-page":"1601855","DOI":"10.1183\/13993003.01855-2016","volume":"49","author":"J Van Ingen","year":"2017","unstructured":"Van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, et al. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J. 2017;49(2):1601855.","journal-title":"Eur Respir J"},{"issue":"2","key":"3553_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10096-017-3120-7","volume":"37","author":"N El-Zeenni","year":"2018","unstructured":"El-Zeenni N, Chanoine S, Recule C, Stahl JP, Maurin M, Camara B. Are guidelines on the management of non-tuberculous mycobacteria lung infections respected and what are the consequences for patients? A French retrospective study from 2007 to 2014. Eur J Clin Microbiol Infect Dis off Publ Eur Soc Clin Microbiol. 2018;37(2):233\u201340.","journal-title":"Eur J Clin Microbiol Infect Dis off Publ Eur Soc Clin Microbiol"},{"issue":"11","key":"3553_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/13696998.2019.1620243","volume":"22","author":"TK Marras","year":"2019","unstructured":"Marras TK, Mirsaeidi M, Vinnard C, Chan ED, Eagle G, Zhang R, et al. Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease. J Med Econ. 2019;22(11):1126\u201333.","journal-title":"J Med Econ"},{"issue":"7","key":"3553_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/cid\/ciaa252","volume":"72","author":"G Abate","year":"2021","unstructured":"Abate G, Stapleton JT, Rouphael N, Creech B, Stout JE, El Sahly HM, et al. Variability in the management of adults with Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis off Publ Infect Dis Soc Am. 2021;72(7):1127\u201337.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"1","key":"3553_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12890-021-01701-5","volume":"21","author":"P Bemer","year":"2021","unstructured":"Bemer P, Peuchant O, Guet-Revillet H, Bador J, Balavoine C, Basille D, et al. Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study. BMC Pulm Med. 2021;21(1):333.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"3553_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/cid\/ciac788","volume":"76","author":"JH Ku","year":"2023","unstructured":"Ku JH, Henkle E, Aksamit TR, Barker A, Brunton AE, Winthrop KL, et al. Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary infection in the US Bronchiectasis and NTM Registry: treatment patterns, adverse events, and adherence to American Thoracic Society\/Infectious Disease Society of America Treatment Guidelines. Clin Infect Dis off Publ Infect Dis Soc Am. 2023;76(2):338\u201341.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"3","key":"3553_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/ciw724","volume":"64","author":"WJ Koh","year":"2017","unstructured":"Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis off Publ Infect Dis Soc Am. 2017;64(3):309\u201316.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"3","key":"3553_CR19","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.","journal-title":"Eur Respir J"},{"issue":"1","key":"3553_CR20","doi-asserted-by":"publisher","first-page":"e000498","DOI":"10.1136\/bmjresp-2019-000498","volume":"7","author":"D Wagner","year":"2020","unstructured":"Wagner D, van Ingen J, van der Laan R, Obradovic M. Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey. BMJ Open Respir Res. 2020;7(1):e000498.","journal-title":"BMJ Open Respir Res"},{"key":"3553_CR21","unstructured":"Network UK. July. Standards of care for people living with non-tuberculous mycobacterial (NTM) disease in the UK. 2024. Version 1. Available at: https:\/\/32520579.isolation.zscaler.com\/profile\/38a3e2fd-3d25-481d-8d62-816d6c9eca61\/zia-session\/?controls_id=da01e921-d435-4274-8f78-1268ac497e1a\u00aeion=fra%26tenant=3550de5b12c7%26user=a5a66cd060cfc81942f0854170d8777067d6711f6d239d052960bd3d2178d210%26original (accessed July 09 2024)."},{"issue":"6","key":"3553_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3201\/eid2206.151642","volume":"22","author":"FC Ringshausen","year":"2016","unstructured":"Ringshausen FC, Wagner D, de Roux A, et al. Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009\u20132014. Emerg Infect Dis. 2016;22(6):1102\u20135.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"3553_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1186\/s12879-021-06825-x","volume":"21","author":"N Veziris","year":"2021","unstructured":"Veziris N, Andr\u00e9jak C, Bou\u00e9e S, et al. Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study. BMC Infect Dis. 2021;21(1):1165.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"3553_CR24","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s10096-018-3315-6","volume":"37","author":"EL Axson","year":"2018","unstructured":"Axson EL, Bloom CI, Quint JK. Nontuberculous mycobacterial disease managed within UK primary care, 2006\u20132016. Eur J Clin Microbiol Infect Dis. 2018;37(9):1795\u2013803.","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03553-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:15:11Z","timestamp":1740150911000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03553-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03553-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants consented to participate before beginning the online survey and prior to the interviews. Given the objectives, the intended use of the collected data, and the methodologies employed, this non-interventional research does not fall under any legislation requiring Institutional Review Board (IRB) approval in Austria, Belgium, France, Germany, Italy, the Netherlands, Spain, or the United Kingdom. In the extend applicable to its non-interventional nature, this research was conducted in accordance with the ethical principles of the Declaration of Helsinki. To comply with the general standards required for scientific publications, the survey obtained ethics approval from the French Institutional Review Board, Comit\u00e9 de Protection des Personnes, Ile de France IV, H\u00f4pital Saint-Louis (N\u00b0IRB 00003835) under the registration number 2021-A01712-39 and methodological approval by the French Data Privacy Agency, Commission Nationale Informatique & Libert\u00e9s under the reference number 2222822 v 0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Part A, the online questionnaire, only contains anonymous data and consent for publication was not applicable. Participants in Part B, the interviews, provided their consent for publication of pseudonymised data before participation in an interview.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MS received research grants from Novartis, Trudell pharma, GSK, and the Tel Aviv League for lung diseases; travel grants- Novartis, Actelion, Boeringer Ingelheim, GSK, Rafa. Speaker\u2019s fees- Astra Zeneca, Boeringer Ingelheim, GSK, Insmed, Teva, Novartis, Kamada, Sanofi. Advisory fees (incl. steering committee membership)- GSK, Boeringer Ingelheim, Kamada, Syncrony medical, Zambon, Vertex pharmaceuticals. DSMB Participation- Bonus therapeutics, Israel. RvL and MO are employees of Insmed, the company that funded the survey. CH, RL and AR are employees of admedicum, which received funding from Insmed to conduct the research. NL received consultancy fees from Insmed, GSK, AN2 Therapeutics, speaker\u2019s fees from GSK and Insmed, and a travel grant from Pfizer. All fees were provided to her institution, not to the author personally.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}